Powered by

-Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma

Oct 04, 2019 - ENP Newswire

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it has completed patient enrollment in the ongoing CANTATA trial.

CANTATA is a global, randomized double-blind clinical trial of the glutaminase inhibitor telaglenastat (CB-839) combined with cabozantinib, a standard of care, in patients with advanced o...